Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOLASE, INCBIOL · Entity 11470 | Chief Financial Officer | June 02, 2023 | June 06, 2023 |
| enVVeno Medical CorpNVNO · Entity 8104 | Chief Financial Officer | May 19, 2025 | May 20, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOLASE, INC
Report date June 02, 2023 · Filed June 06, 2023 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 90,563 |
Reported balance
After 2023-06-02 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2023-06-02 · Grant · Acquired 58,000 · Balance 90,563 F1: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent. F2: The restricted stock unit award vests as follows: (i) one-half of the restricted stock units shall vest on May 9, 2024, and (ii) one-half of the restricted stock units shall vest on May 9, 2025, subject to the Reporting Person's continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent.
F2: The restricted stock unit award vests as follows: (i) one-half of the restricted stock units shall vest on May 9, 2024, and (ii) one-half of the restricted stock units shall vest on May 9, 2025, subject to the Reporting Person's continued service with the Company.
enVVeno Medical Corp
Report date May 19, 2025 · Filed May 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2035-05-19 | Direct | 350,000 |
Reported balance
After 2025-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-19 · Grant · Acquired 350,000 · Balance 350,000 F1: The stock option was granted pursuant to the registrant's Amended and Restated 2016 Omnibus Incentive Plan, as amended. F2: The stock options shall vest quarterly, over a three (3) year period, with a one (1) year cliff, subject to the reporting person's continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option was granted pursuant to the registrant's Amended and Restated 2016 Omnibus Incentive Plan, as amended.
F2: The stock options shall vest quarterly, over a three (3) year period, with a one (1) year cliff, subject to the reporting person's continued service with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2025 Filed May 20, 2025 16:40 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 350,000 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0001641172-25-011744 · ownership.xml · derivative · entry 1 Bright Jennifer · CIK 0001937848 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2035-05-19 F1 · security: The stock option was granted pursuant to the registrant's Amended and Restated 2016 Omnibus Incentive Plan, as amended. F2 · derivative.exercise_date: The stock options shall vest quarterly, over a three (3) year period, with a one (1) year cliff, subject to the reporting person's continued service with the Company. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:36 UTC Amendment | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 58,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034898 · doc4a.xml · derivative · entry 1 Bright Jennifer · CIK 0001937848 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,563 Underlying: Common Stock · 58,000 shares Expires not disclosed F1 · derivative.exercise_price: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent. F2 · derivative.exercise_date: The restricted stock unit award vests as follows: (i) one-half of the restricted stock units shall vest on May 9, 2024, and (ii) one-half of the restricted stock units shall vest on May 9, 2025, subject to the Reporting Person's continued service with the Company. F2 · derivative.expiration_date: The restricted stock unit award vests as follows: (i) one-half of the restricted stock units shall vest on May 9, 2024, and (ii) one-half of the restricted stock units shall vest on May 9, 2025, subject to the Reporting Person's continued service with the Company. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:29 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 58,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034892 · doc4.xml · derivative · entry 1 Bright Jennifer · CIK 0001937848 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,563 Underlying: Common Stock · 58,000 shares Expires not disclosed F1 · derivative.exercise_price: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent. F2 · derivative.exercise_date: The restricted stock unit award vests as follows: (i) one-half of the restricted stock units shall vest on May 9, 2024, and (ii) one-half of the restricted stock units shall vest on May 9, 2025, subject to the Reporting Person's continued service with the Company. F2 · derivative.expiration_date: The restricted stock unit award vests as follows: (i) one-half of the restricted stock units shall vest on May 9, 2024, and (ii) one-half of the restricted stock units shall vest on May 9, 2025, subject to the Reporting Person's continued service with the Company. F3 · derivative.expiration_date: The restricted stock unit award vests as follows: (i) one-half of the restricted stock units shall vest on the twelve-month anniversary of date of grant, and (ii) one-half of the restricted stock units shall vest on the twenty-fourth month anniversary of the date of grant, subject to the Reporting Person's continued service with the Company. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 16:51 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 6,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045627 · doc4.xml · derivative · entry 2 Bright Jennifer · CIK 0001937848 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,563 Underlying: Common Stock · 6,663 shares Expires not disclosed F1 · derivative.exercise_price: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent. F3 · derivative.exercise_date: The restricted stock unit award vests on August 14, 2022, subject to the Reporting Person's continued service with the Company. F3 · derivative.expiration_date: The restricted stock unit award vests on August 14, 2022, subject to the Reporting Person's continued service with the Company. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 16:51 UTC | BIOLASE, INC BIOL · Entity 11470 | GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045627 · doc4.xml · derivative · entry 1 Bright Jennifer · CIK 0001937848 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,900 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent. F2 · derivative.exercise_date: The restricted stock unit award vests as follows: (i) one-half of the restricted stock units shall vest on the twelve-month anniversary of date of grant, and (ii) one-half of the restricted stock units shall vest on the twenty-fourth month anniversary of the date of grant, subject to the Reporting Person's continued service with the Company. F2 · derivative.expiration_date: The restricted stock unit award vests as follows: (i) one-half of the restricted stock units shall vest on the twelve-month anniversary of date of grant, and (ii) one-half of the restricted stock units shall vest on the twenty-fourth month anniversary of the date of grant, subject to the Reporting Person's continued service with the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.